Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could caffeine help save newborn brains? major trial launches

NCT ID NCT06855108

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving caffeine to newborns with hypoxic ischemic encephalopathy (HIE) can reduce death or long-term disability. HIE is a brain injury caused by lack of oxygen around birth. The trial will enroll 830 full-term infants and give them either caffeine or a placebo within six hours of birth. Researchers will follow the children until 18-22 months of age to compare outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
caffeine citrate oral solution
What this could lead to
If it works, this could provide a simple, low-cost treatment to lower the risk of death or long-term disability in newborns with HIE.
What could go wrong
This is an early-stage trial, and caffeine may not improve outcomes. The study is still recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 830 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 6 hours

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participant Inclusion Criteria: Infants who meet all the following criteria are eligible for enrollment as study participants: 1. Liveborn infants ≥36 weeks 2. Birth weight ≥1800 grams 3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria: 1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria: * pH \<7.0; or * Base Deficit ≥16 mmol/L; or * Lactate \>8 mmol/L. 2. Criterion #2: Participant must meet all of the following three criteria: i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria: * POC pH 7.0-7.15; or * Base Deficit 10.0-15.9 mmol/L; or * Lactate 6-8 mmol/L. ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture). iii. Any of the following criteria: * 10-minute Apgar \<5; or * Need for assisted ventilation initiated at birth and continued for ≥10 minutes 4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria: 1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or 2. A clinical diagnosis of seizure in the first six hours after birth. Participant Exclusion Criteria: Infants who meet any of the following criteria are not eligible for enrollment as study participants: 1. Home births 2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery 3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment. 4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement. 5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant. 6. Infants who will be unavailable to complete follow-up visits. 7. Infants who have received caffeine after delivery. 8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol. 9. Enrollment in another trial that will impact participation in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypoxic-ischemic encephalopathy (HIE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aga Khan University

    NOT_YET_RECRUITING

    Karachi, Pakistan

  • ICDDR,B

    RECRUITING

    Saidpur, Bangladesh

  • Institute of Nutrition of Central America And Panama (INCAP)

    RECRUITING

    Chimaltenango, Guatemala

  • KLE University's J N Medical College

    NOT_YET_RECRUITING

    Belagavi, India

  • Kinshasa School of Public Health

    NOT_YET_RECRUITING

    Kinshasa, Democratic Republic of the Congo

  • Lata Medical Research Foundation

    NOT_YET_RECRUITING

    Nagpur, India

  • University Teaching Hospital

    RECRUITING

    Lusaka, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.